| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 398 | 2021 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 369 | 2017 |
| Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial LE Ferri, S Ades, T Alcindor, M Chasen, V Marcus, M Hickeson, G Artho, ... Annals of oncology 23 (6), 1512-1517, 2012 | 122 | 2012 |
| Crizotinib in patients with MET-amplified NSCLC DR Camidge, GA Otterson, JW Clark, SHI Ou, J Weiss, S Ades, GI Shapiro, ... Journal of Thoracic Oncology 16 (6), 1017-1029, 2021 | 103 | 2021 |
| Crizotinib in patients (pts) with MET-amplified non-small cell lung cancer (NSCLC): Updated safety and efficacy findings from a phase 1 trial. DR Camidge, GA Otterson, JW Clark, SHI Ou, J Weiss, S Ades, U Conte, ... Journal of Clinical Oncology 36 (15_suppl), 9062-9062, 2018 | 87 | 2018 |
| Tumor oncogene (KRAS) status and risk of venous thrombosis in patients with metastatic colorectal cancer S Ades, S Kumar, M Alam, A Goodwin, D Weckstein, M Dugan, ... Journal of Thrombosis and Haemostasis 13 (6), 998-1003, 2015 | 77 | 2015 |
| Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice. S Ades Oncology 23 (2), 162-162, 2009 | 77 | 2009 |
| Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis NB Adams, PL Lutsey, AR Folsom, DH Herrington, CT Sibley, NA Zakai, ... Journal of Thrombosis and Haemostasis 11 (6), 1078-1084, 2013 | 73 | 2013 |
| Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy … P Gibbs, V Heinemann, NK Sharma, J Taieb, J Ricke, M Peeters, ... Clinical colorectal cancer 17 (4), e617-e629, 2018 | 67 | 2018 |
| Selected class I and class II HLA alleles and haplotypes and risk of high‐grade cervical intraepithelial neoplasia S Ades, A Koushik, E Duarte‐Franco, N Mansour, J Arseneau, ... International journal of cancer 122 (12), 2820-2826, 2008 | 56 | 2008 |
| In-advance end-of-life discussions and the quality of inpatient end-of-life care: a pilot study in bereaved primary caregivers of advanced cancer patients M Mori, D Ellison, T Ashikaga, U McVeigh, A Ramsay, S Ades Supportive Care in Cancer, 1-8, 2012 | 49 | 2012 |
| Randomized phase II study of loratadine for the prevention of bone pain caused by pegfilgrastim J Moukharskaya, DM Abrams, T Ashikaga, F Khan, J Schwartz, K Wilson, ... Supportive Care in Cancer 24, 3085-3093, 2016 | 29 | 2016 |
| Lens changes in hereditary hyperferritinemia-cataract syndrome A Chang-Godinich, S Ades, D Schenkein, D Brooks, D Stambolian, ... American journal of ophthalmology 132 (5), 786-788, 2001 | 29 | 2001 |
| Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory cancer clinic CE Holmes, S Ades, S Gilchrist, D Douce, K Libby, B Rogala, E Parenteau, ... JCO Oncology Practice 16 (9), e868-e874, 2020 | 28 | 2020 |
| Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma M Sudarshan, T Alcindor, S Ades, A Aloraini, M van Huyse, J Asselah, ... Annals of surgical oncology 22, 324-330, 2015 | 27 | 2015 |
| NKX2. 2, PDX-1 and CDX-2 as potential biomarkers to differentiate well-differentiated neuroendocrine tumors MX Yang, RF Coates, A Ambaye, V Cortright, JM Mitchell, AM Buskey, ... Biomarker Research 6, 1-7, 2018 | 24 | 2018 |
| Risk factors for cancer‐associated venous thromboembolism: the venous thromboembolism prevention in the ambulatory cancer clinic (VTE‐PACC) study DR Douce, CE Holmes, M Cushman, CD MacLean, S Ades, NA Zakai Journal of Thrombosis and Haemostasis 17 (12), 2152-2159, 2019 | 18 | 2019 |
| Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study M Mori, Y Ji, S Kumar, T Ashikaga, S Ades International journal of clinical oncology 22, 397-404, 2017 | 16 | 2017 |
| Nanoparticle‐based targeted cancer strategies for non‐invasive prostate cancer intervention NH Farina, A Zingiryan, MA Vrolijk, SD Perrapato, S Ades, GS Stein, ... Journal of cellular physiology 233 (9), 6408-6417, 2018 | 13 | 2018 |
| Nivolumab‐induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy M Gergi, KK Landry, S Ades, M Barry, NA Zakai, DA Herrera The oncologist 25 (12), 1009-1012, 2020 | 12 | 2020 |
